Hyperbaric oxygen therapy (HBOT) has shown to be beneficial in the standard of care in treating radiation proctitis. It also helps heal radiation cystitis and radionecrosis. HBOT is approved by the FDA, Medicare, and by numerous private insurance companies for treating radiation proctitis.
Traditional treatment approaches such as pharmacotherapy, endoscopic interventions, and surgery have shown limited success and often come with associated risks.
Hyperbaric oxygen therapy (HBOT) has shown to be beneficial in the standard of care in treating radiation proctitis. It also helps heal radiation cystitis and radionecrosis. HBOT is approved by the FDA, Medicare, and by numerous private insurance companies for treating radiation proctitis.
Traditional treatment approaches such as pharmacotherapy, endoscopic interventions, and surgery have shown limited success and often come with associated risks.
Hyperbaric oxygen therapy helps enhance tissue oxygenation, promote neovascularization, and support tissue repair processes. In the context of radiation proctitis, HBOT has demonstrated several key benefits:
Existing evidence supports the integration of HBOT into the therapeutic standard of care for radiation proctitis, including the following studies:
The American Society of Colon and Rectal Surgeons' clinical practice guidelines for the treatment of chronic radiation proctitis recommend hyperbaric oxygen therapy as an effective treatment modality to reduce bleeding in patients with radiation proctitis.
Hyperbaric oxygen therapy improved healing in patients with refractory radiation proctitis. Other medical management requirements were discontinued, and advanced interventions were largely avoided. Patients' bowel-specific quality of life improved.
Have more Questions?